Led 4 person team to manage US flagship peritoneal dialysis cycler. -Developed and executed a product improvement roadmap to extend the lifecycle of the cycler portfolio, resulting in $250M annual revenues and 10% compound annual growth rate (CAGR).-Led cross-functional software and digital teams to secure FDA 510(k) clearance and commercialize 1st SaaS-connected health cycler for remote patient management to reduce patient attrition by 90%.-Gathered customer insight and competitive intelligence analytics to drive value engineering (VE) for portfolio's disposables (10M units sold annually) to achieve EBIT targets with 40% cost savings.-Implemented operational efficiencies in replacement product shipping by leading cross-functional teams of tech support, customer service, and operations, delivering $2M+ cost savings in year 1.-Collaborated with senior leadership to align product strategies with business objectives post merger of Fresenius Medical Care with NxStage Medical, improving overall organizational performance.-Managed 2-person Telehealth team to sustain 76% reduction in symptom code product replacement rates and scaled processes across field clinical teams to reduce calls to Tech Support by 25%.-Mentored high-performing direct reports utilizing effective engagement and communications skills to build their confidence to lead projects, make data-driven decisions, and present to senior executives.-Led preparation and pitch of new product concepts and strategies to steering committees and communicated strategic plans and project status to senior leadership and key stakeholders.-Built relationships with key opinion leaders (KOLs) on various advisory boards to assess and refine concepts for further product development, usability and market segmentation.-Worked within a global team to leverage product efficiencies, harmonization, and competitive insights, driving strategic decision-making and enhancing market positioning for a global product roadmap.

Managed US flagship peritoneal dialysis cycler portfolio.-Managed cycler portfolio for 22,000 patients, leading cross-functional teams to achieve strategic goals in sales, profitability, and product quality, growing market share 9% to 38% since 2008 launch.-Led software and hardware product development upgrades to the cycler with R&D and regulatory based on voice of customer and key quality metrics, reducing product replacement rates by 72%.-Partnered with Customer Experience (CX) Team to design satisfaction surveys for cycler portfolio, identifying patient preferences and key experience drivers, achieving world class 80% NPS.-Developed comprehensive product documentation, including user requirements and guides, labeling, packaging, sales and customer training plans and digital educational tools, and launch plans.

Managed peritoneal dialysis drug fluids, ancillaries and services portfolio.-Managed lifecycle 70+ SKU drug fluid and ancillary product portfolio, including pre-development and rationalization, achieving $150M annual revenues.-Led foundational global harmonization efforts for a new drug fluid container system into the US market, securing FDA approval and commercializing in the US in 2020, resulting in $8M in annual savings.-Employed the Stage Gate process to develop an innovative drug fluid, securing FDA approval in 2012 to extend patient time on therapy with a 73% more biocompatible drug.-Collaborated with UX/UI designers to develop the company's first online product ordering portal, providing user-centric interfaces and improving customer service efficiencies.-Coordinated with IT, customer service, and a third-party vendor to develop, pilot, and launch an electronic prescription portal/app, improving physician response times.-Crafted product positioning and messaging to guide marketing communications, sales strategies, presentations, videos, websites and advertising campaigns, driving technology value proposition.-Supported corporate budget planning, long-range patient projections and product forecasts, and global market surveys to drive strategic plans and decision-making to achieve financial goals.

Managed Synthetic Products & Services portfolio.

Managed Process Monitoring Services portfolio.

Managed Genetic Systems portfolio.

Managed Genetic Databases & Sequencing portfolio.

Managed Consumables portfolio for molecular biology instruments.

Researched Protein Therapeutics.

Contributed to the sequencing efforts to support the Human Genome Project.